CDNA News and Press, CareDx Inc. From 05/03/24

2024-05-03 07:15:00 ET Summary Baron is an asset management firm focused on delivering growth equity investment solutions known for a long-term, fundamental, active approach to growth investing. During the first quarter of 2024, Baron Discovery Fund® (the Fund) was up 4.57% (...

2024-05-01 10:30:04 ET Craig-Hallum analyst issues BUY recommendation for CDNA on May 1, 2024 08:10AM ET. CDNA was trading at $7.76 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst recommendations are : 3 - Buy recommendations ...

2024-05-01 10:00:09 ET More on Health Care Select Sector SPDR XLV: Pivotal Week Of Earnings For Healthcare Stocks XLV: Fundamentals Don't Support Overweighting Health Care XLV: Low-Cost Exposure To A Defensive Sector, While Achieving Strong Performance 19 out...

A look at the top 10 most actives in the United States Akanda Corp. (AKAN) rose 52.9% to $0.1422 on volume of 108,274,564 shares CytomX Therapeutics Inc. (CTMX) rose 71.8% to $2.8 on volume of 31,588,176 shares Getaround Inc. (GETR) rose 35.9% to $0.2754 on volume of 26,693,135 shares P...

CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced it will report financial results for the f...

CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers — today announ...

2024-04-17 16:00:04 ET Mason Carrico from Stephens issued a price target of $15.00 for CDNA on 2024-04-17 14:04:00. The adjusted price target was set to $15.00. At the time of the announcement, CDNA was trading at $8.29. The overall price target consensus is at $39.50 wi...

2024-04-16 16:07:02 ET More on CareDx CareDX pares loss, gains after jury awards $96M to Natera in patent dispute (update) Seeking Alpha’s Quant Rating on CareDx Historical earnings data for CareDx Read the full article on Seeking Alpha For fur...

CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ – a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients – has appointed John W. Hanna...

2024-04-10 09:42:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...